SLU-PP-332
pan-ERR agonist SLU-PP-332
REC PPT-SLU-PP-332 // REV 2026-10-04 // assessment changes are logged, never silent
A synthetic agonist of the estrogen-related receptors that produced exercise-like metabolic changes in mice; there is no human data of any kind, and the phrase exercise in a pill describes the marketing rather than the literature.
What it is
A small synthetic molecule rather than a peptide: a pan-agonist of the estrogen-related receptors ERR-alpha, ERR-beta and ERR-gamma, reported from the laboratory of Thomas Burris. Those nuclear receptors govern mitochondrial biogenesis and oxidative metabolism in muscle, heart and liver.
What it does
Studied in rodents for running endurance, energy expenditure, fatty-acid oxidation and the metabolic profile of diet-induced obesity. It has not been studied in humans for any purpose.
Does it work?
Europe PMC returns 30 records for the term and a large share of those are reviews and commentary rather than new experiments; ClinicalTrials.gov holds no registered study, interventional or observational, and there are no randomised trials. The primary findings are two mouse papers from the originating laboratory: a 2023 report in ACS Chemical Biology describing an ERR-alpha-dependent acute exercise response and increased running capacity in mice, and a 2024 report in the Journal of Pharmacology and Experimental Therapeutics describing raised energy expenditure, reduced fat mass and improved insulin sensitivity in diet-induced obese and ob/ob mice. Two of the most recent papers on the compound come from anti-doping chemistry, characterising its metabolites so that testing laboratories can detect it, which places the compound in athletes before it has reached a single trial. A 2026 review in Trends in Endocrinology and Metabolism argues directly that exercise pills of this class cannot reproduce the systemic environment of exercise.
Claims vs data
Each marketing claim, tagged by what the evidence actually supports.
| Activates ERR-alpha, ERR-beta and ERR-gamma in cell-based assays | preclinical only |
| Increases running endurance in mice | animal data only |
| Reduces fat mass and improves insulin sensitivity in obese mouse models | animal data only |
| Delivers the benefits of exercise in humans without exercising | overreach |
Reference figures
Quoted from published reference material. These are not Peptuity recommendations.
molecular data — PubChem CID 5338394
The evidence, counted
Live counts from Europe PMC and ClinicalTrials.gov.
30 publications indexed, 0 registered interventional studies, no randomised controlled trials indexed. Evidence is minimal.
SRC // EUROPE PMC + CTGOV // "SLU-PP-332" // FETCHED 2026-10-04 // 30 RECORDS
Most-cited literature
-
[01]
Nuclear receptors in health and disease: signaling pathways, biological functions and pharmaceutical interventions
Jin P, Duan X, Huang Z, Dong Y, Zhu J, Guo H, Tian H, Zou CG, Xie K. · Signal Transduct Target Ther 2025 · 58 citations · DOI 10.1038/s41392-025-02270-3
-
[02]
Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function
Xu W, Billon C, Li H, Wilderman A, Qi L, Graves A, Rideb JRDC, Zhao Y, · Circulation 2024 · 58 citations · DOI 10.1161/circulationaha.123.066542
-
[03]
International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023
Burris TP, de Vera IMS, Cote I, Flaveny CA, Wanninayake US, Chatterjee · Pharmacol Rev 2023 · 42 citations · DOI 10.1124/pharmrev.121.000436
-
[04]
Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity
Billon C, Sitaula S, Banerjee S, Welch R, Elgendy B, Hegazy L, Oh TG, · ACS Chem Biol 2023 · 40 citations · DOI 10.1021/acschembio.2c00720
Regulatory status
Formal, dated regulatory actions.
WADA — Prohibited List 2026
Prohibited in sport — WADA S0 (substance without any health-authority approval)
Common questions
Has SLU-PP-332 ever been given to a human?
Not in any published or registered study. ClinicalTrials.gov holds no record for the compound, and Europe PMC returns no human study among the 30 records for the term. Everything reported about it comes from cell assays and mice.
Is it a peptide?
No. It is a small synthetic molecule that acts on nuclear receptors inside the cell, which is a different pharmacology from the injectable peptides it is usually listed alongside. The SLU-PP prefix is a laboratory compound code, not a peptide designation.
What did the mouse endurance result actually measure?
Treadmill running time and distance in mice, together with changes in oxidative muscle fibre type and gene expression. That is a rodent performance measurement over days; it is not evidence about human endurance, body composition or health outcomes.
Is it approved anywhere, or allowed in sport?
It holds no approval from any regulator, including the FDA and the Saudi FDA, and it is not a licensed medicine anywhere. Because it has no human therapeutic approval anywhere in the world, it falls inside the WADA S0 category of non-approved substances, prohibited at all times in and out of competition.
Related compounds
MOTS-c
Mitochondrial-derived peptide. Interesting biology, minimal human data.
5-Amino-1MQ
Small-molecule NNMT inhibitor, not a peptide. Preclinical only.
NAD+
A coenzyme, not a peptide. Precursors have better human data than NAD+ itself.
SS-31
Mitochondria-targeted peptide with genuine clinical development history.